Short Interest in Azitra, Inc. (NYSEAMERICAN:AZTR) Increases By 144.1%

Azitra, Inc. (NYSEAMERICAN:AZTR) was the target of a large growth in short interest in February. As of February 15th, there was short interest totalling 1,990,000 shares, a growth of 144.1% from the January 31st total of 815,400 shares. Currently, 26.4% of the shares of the company are sold short. Based on an average daily trading volume, of 6,550,000 shares, the short-interest ratio is presently 0.3 days.

Azitra Trading Up 1.7 %

Shares of NYSEAMERICAN:AZTR traded up $0.01 during midday trading on Friday, reaching $0.36. 422,255 shares of the company traded hands, compared to its average volume of 10,773,634. Azitra has a 12 month low of $0.23 and a 12 month high of $12.00.

Hedge Funds Weigh In On Azitra

An institutional investor recently raised its position in Azitra stock. Virtu Financial LLC boosted its holdings in Azitra, Inc. (NYSEAMERICAN:AZTR) by 196.4% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 63,180 shares of the company’s stock after purchasing an additional 41,866 shares during the period. Virtu Financial LLC owned approximately 0.83% of Azitra worth $27,000 at the end of the most recent reporting period. Institutional investors own 11.16% of the company’s stock.

About Azitra

Azitra, Inc, an early-stage biopharmaceutical company, develops therapies for precision dermatology using engineered proteins and live biotherapeutic products to treat skin diseases. It develops ATR-12, a genetically modified strain of S. epidermidis, which is in Phase Ib clinical trial for treating Netherton syndrome, a skin disease.